Edit
Ariceum Therapeutics
http://www.ariceum-therapeutics.com/Last activity: 29.10.2025
Probably Closed
Ariceum Therapeutics (Ariceum) is a private, clinical stage radiopharmaceutical company currently focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. The name Ariceum is an anagram of ‘Marie Curie’. Ariceum’s lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan (“satoreotide”) is an antagonist of the somatostatin type 2 (SST2) receptor which is overexpressed in neuroendocrine tumours (NETs), some aggressive cancers such as small cell lung cancer (SCLC), all of which have few treatment options and poor prognosis. Satoreotide is being developed as a ‘theranostic’ pair for the combined diagnosis and targeted radionuclide treatment of these tumours.
Ariceum Therapeutics, launched in 2021, acquiring all rights from Ipsen. Ipsen remains a shareholder in the Company. Ariceum is headquartered in Berlin, with operations in Germany, Switzerland and Australia.
Ariceum Therapeutics, launched in 2021, acquiring all rights from Ipsen. Ipsen remains a shareholder in the Company. Ariceum is headquartered in Berlin, with operations in Germany, Switzerland and Australia.
Location: Germany, Berlin
Total raised: $79.19M
Investors 2
| Date | Name | Website |
| 18.04.2023 | Earlybird ... | earlybird.... |
| - | Andera Par... | anderapart... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 18.04.2023 | Series A | $52.37M | Andera Par... |
| 13.06.2022 | Series A | $26.82M | HealthCap |
Mentions in press and media 14
| Date | Title | Description |
| 29.10.2025 | Earlybird Health promotes two new partners as firm deepens biotech and analytics focus | Life sciences investor Earlybird Health has promoted Dr. Rabab Nasrallah and Dr. Christoph Massner to Partners. Both new partners have led the firm's strategy across biotech, data-enabled therapeutics and medtech. Earlybird Health, part of ... |
| 12.08.2024 | The endgame: 10 European startups aiming to defeat cancer | Cancer remains one of the most pressing global health challenges, claiming millions of lives each year and impacting countless more. Despite significant advancements in research and treatment, the fight against cancer demands continuous inn... |
| 09.07.2024 | Andera Partners co-leads a €63 million Series A round for Munich-based autoimmune biotech SciRhom | Andera Partners, a leading European private equity player, announced today that it is co-leading a € 63 million ($ 70 million) Series A financing for SciRhom, a biopharmaceutical company pioneering the development of first-in-class therapeu... |
| 12.05.2023 | UCB and Ariceum Therapeutics sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and Cancer | Berlin, Germany, and Brussels, Belgium, 11 May 2023 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers,and UCB (EURONEXT BRUSS... |
| 18.04.2023 | Ariceum Therapeutics Announces Extension of Series A Financing to EUR 47.75M to Advance its Next Generation Radiopharmaceutical Clinical Pipeline | Berlin, Germany, 18 April 2023 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announces the successful completion o... |
| 18.04.2023 | Andera Partners co-leads a Series A extension round of € 47.75 million for radiopharmaceutical company Ariceum Therapeutics | Andera Partners, a leading European private equity player, today announces the successful completion of a Series A extension financing, co-led with Earlybird Venture Capital, for Ariceum Therapeutics (Ariceum), a radiopharmaceutical special... |
| 18.04.2023 | Ariceum Therapeutics Raises €25M; Extends Series A to €47.75M | Ariceum Therapeutics, a Berlin, Germany-based biotech company developing radiopharmaceutical products, raised an additional €25M in the Series A financing announced in June 2022. The extension round was co-led by new investors Andera Partne... |
| 02.02.2023 | Ariceum Therapeutics Appoints Radioligand Expert, Germo Gericke, M.D., as Chief Medical Officer | Berlin, Germany, 1 February 2023 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, is pleased to a... |
| 28.10.2022 | Ariceum Therapeutics and AmbioPharm Enter Strategic Manufacturing and Supply Partnership | BERLIN, Germany and NORTH AUGUSTA, S.C., USA, 27th October 2022 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to... |
| 13.06.2022 | Ariceum Therapeutics Raises EUR 25M in Series A Funding | Ariceum Therapeutics, a Berlin, Germany-based biotech company, raised EUR25M in Series A funding. Ariceum was co-founded by EQT Life Sciences (formerly LSP) and HealthCap who also co-led the financing that was joined by Pureos Bioventures. ... |
Show more